How did Catalyst's revenue and expenses shift in Q4 2024?

Catalyst Pharmaceuticals experienced a notable increase in revenue and a slight rise in expenses during Q4 2024, with net income remaining stable compared to the previous quarter:

1. **Revenue Shift**:
- The total revenue for Catalyst Pharmaceuticals in Q4 2024 was $489.33 million. This is a significant increase from the previous quarter, indicating a strong product revenue performance.
- The company's product revenue, net, contributed $347.52 million to the total revenue, which is a substantial portion of the overall revenue.
- Additionally, the company reported $2.41 million in license and other revenue, which, although smaller, still contributed to the overall revenue growth.
2. **Expense Shift**:
- Catalyst Pharmaceuticals incurred a cost of goods sold (COGS) of $21.64 million, which represents a 2.8% increase from the previous quarter. This suggests that the cost of producing and delivering their products has risen slightly.
- The company's research and development (R&D) expenses were $3.8 million, which is consistent with the previous quarter, indicating that there has been no significant change in the R&D spending.
- Selling, general, and administrative (SG&A) expenses were $53.54 million, which is also consistent with the previous quarter, suggesting that there has been no significant change in these expenses.
3. **Net Income Stability**:
- Despite the revenue increase and minor expense changes, Catalyst Pharmaceuticals reported a net income of $55.94 million in Q4 2024, which is the same as the net income reported in the previous quarter.
- This indicates that the company's increased revenue has been effectively managed to maintain profitability, with no significant impact on net income.

In conclusion, Catalyst Pharmaceuticals saw a significant boost in revenue during Q4 2024, driven primarily by product revenue. While there was a slight increase in COGS, the company managed to maintain its net income, demonstrating effective cost management and a strong financial performance in the period.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|CPRX|CPRX.O|Catalyst|20240101-2024|License and Other|2407000|186|
|CPRX|CPRX.O|Catalyst|20240101-2024|License and Other|2396000|186|
|CPRX|CPRX.O|Catalyst|20240101-2024|License and Other|125000|186|
|CPRX|CPRX.O|Catalyst|20240101-2024|License and Other|68000|186|
|CPRX|CPRX.O|Catalyst|20240101-2024|Product Revenue, Net|9.8441E7|186|
|CPRX|CPRX.O|Catalyst|20240101-2024|License and Other|68000|186|

|code|Ticker|Name|Date|Cost of Goods Sold|R&D Expenses|Advertising and Marketing Expenses|market_code|
|---|---|---|---|---|---|---|---|
|CPRX|CPRX.O|Catalyst|2024 Q1|1.252E7|2581000||186|
|CPRX|CPRX.O|Catalyst|2024 Q2|1.5405E7|2985000||186|
|CPRX|CPRX.O|Catalyst|2024 Q3|1.9277E7|3284000||186|
|CPRX|CPRX.O|Catalyst|2024 Q4|2.1643E7|3798000||186|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|CPRX|CPRX.O|Catalyst|2024 Q1|-21.283143939393938|2.3275E7|186|
|CPRX|CPRX.O|Catalyst|2024 Q2|8.029235739632433|4.0794E7|186|
|CPRX|CPRX.O|Catalyst|2024 Q3|242.64725003250553|4.3884E7|186|
|CPRX|CPRX.O|Catalyst|2024 Q4|60.5326598553553|5.5936E7|186|